[ad_1]
Moderna has announced the start of testing of a new type of vaccine specially designed to target the Corona mutation discovered in South Africa.
The company said, according to the US network NBC, that it had shipped doses of the new vaccine to the National Institutes of Health for clinical trials, and this development is part of the company’s efforts to deal with new mutations in the new vaccine. Corona and overcome the constantly changing virus.
Company CEO Stephan Bancel said: “Moderna is committed to making as many updates to its vaccine as necessary to bring the outbreak under control.”
It is reported that there is no evidence so far that the coronavirus has mutated in a way that would make it capable of fighting current vaccines, but the possibility remains a major concern for scientists around the world. .
Early studies showed that the Moderna vaccine had less protection against the South African strain, but the company said that “the observed level of equivalent antibodies that can bind to viruses and prevent them from reaching cells remained at above protection levels “.
The South African strain is among the most dangerous viral mutations today, as it is able to avoid antibodies that target older strains of the Corona virus.
Cases of the British viral strain have been reported in more than 80 countries and more than half of the states in the United States, while the South African strain has been detected in at least 40 countries, including the United States.
Moderna has already started testing with a third dose of its vaccine as a booster dose in people who have already received two doses, but will now begin clinical trials to assess safety and effectiveness. The company will also be testing a “versatile booster filter” that combines its original vaccine with specific release in a single dose.
As part of the new trials, Moderna will assess immune responses in people who have already been vaccinated, as well as in participants who are receiving vaccines for the first time.
Source link
